Cherwell Online1h
Oxford-GSK cancer vaccine research receives £50 investment
GSK, the tenth biggest pharmaceutical company in the world, is investing £50 million to establish the GSK–Oxford Cancer Immuno-Prevention Programme, aimed at advancing the development of a ...
ROSEN, LEADING TRIAL ATTORNEYS, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK
NEW YORK, NY / ACCESS Newswire / February 15, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between ...
FDA approves GSK vaccine to combat meningococcal infections
Meningococcal infections can lead to severe, sometimes deadly, bloodstream infections, and severe swelling in the brain and ...
The Financial Express7h
The rise of Glenmark’s Telma: How this blood pressure drug became a Rs 1,000 crore brand
A 2015 study by Harvard Business Publishing Education revealed that Telma was introduced by Glenmark in 2003 at a time when ...
Here's Why We're Wary Of Buying GSK's (LON:GSK) For Its Upcoming Dividend
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might ...
Here’s the dividend forecast for GSK shares through to 2026!
City brokers expect dividends on GSK shares will keep marching higher. Is the FTSE 100 share a top passive income stock to ...
ENDPOINTS NEWS15h
GSK fol­lows Pfiz­er in meningo­coc­cal vac­cine race with new FDA nod
GSK has snagged FDA approval for its 5-in-1 meningococcal vaccine, propelling it to a familiar position: rivaling Pfizer.
US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
FiercePharma17h
With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
GSK Q3FY25 Results: Net profit jumps 4X to ₹229 crore; revenue improves 18%
GlaxoSmithKline Pharmaceuticals Ltd reported an 18% revenue increase to ₹946 crore for Q3 ended December 31, 2024, with a ...
GSK Pharma put volume heavy and directionally bearish
Pharma with 2,330 puts trading, or 1.1x expected. Most active are 2/14 weekly 36 puts and 2/28 weekly 36 puts, ...